Genmab A/S (NASDAQ:GMAB) Upgraded at Wall Street Zen
Wall Street Zen upgraded Genmab A/S (NASDAQ:GMAB) from a "hold" to a "buy" rating. Other analysts, including Guggenheim and HC Wainwright, also issued buy ratings, while Zacks Research downgraded it to "hold." The stock has a consensus rating of "Moderate Buy" with an average target price of $39.75. Genmab A/S reported strong quarterly earnings, surpassing estimates, and has seen significant institutional investment.
Genmab A/S (NASDAQ:GMAB - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a note issued to investors on Saturday.
Other research analysts have also issued reports about the stock. Guggenheim raised shares of Genmab A/S from a "neutral" rating to a "buy" rating and set a $43.00 price target on the stock in a research note on Tuesday, September 23rd. Zacks Research lowered shares of Genmab A/S from a "strong-buy" rating to a "hold" rating in a report on Friday, October 31st. Johnson Rice reissued a "buy" rating on shares of Genmab A/S in a research note on Monday, October 27th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Genmab A/S in a research report on Wednesday, October 8th. Finally, HC Wainwright lifted their price target on shares of Genmab A/S from $40.00 to $41.00 and gave the company a "buy" rating in a research report on Monday, November 10th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $39.75.
Get Our Latest Report on Genmab A/S
Genmab A/S Trading Up 1.4%
Genmab A/S stock opened at $30.45 on Friday. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $33.65. The stock's 50 day simple moving average is $30.20 and its two-hundred day simple moving average is $25.08. The firm has a market cap of $19.55 billion, a PE ratio of 12.96, a P/E/G ratio of 1.56 and a beta of 0.96.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.65 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.17. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $975.40 million. Genmab A/S had a net margin of 41.36% and a return on equity of 23.98%. Genmab A/S has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Genmab A/S will post 1.45 EPS for the current year.
Institutional Trading of Genmab A/S
A number of institutional investors have recently bought and sold shares of GMAB. Foresight Group Ltd Liability Partnership purchased a new position in Genmab A/S during the 1st quarter valued at about $954,000. Vident Advisory LLC purchased a new position in Genmab A/S during the first quarter worth $242,000. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Genmab A/S in the second quarter worth $257,000. Campbell & CO Investment Adviser LLC boosted its stake in shares of Genmab A/S by 293.1% during the second quarter. Campbell & CO Investment Adviser LLC now owns 107,217 shares of the company's stock valued at $2,215,000 after acquiring an additional 79,945 shares during the last quarter. Finally, Parallel Advisors LLC raised its position in shares of Genmab A/S by 377.5% in the second quarter. Parallel Advisors LLC now owns 3,720 shares of the company's stock valued at $77,000 after buying an additional 2,941 shares during the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.
About Genmab A/S
(Get Free Report)Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Further Reading
- Five stocks we like better than Genmab A/S
- How to Buy Gold Stock and Invest in Gold
- A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves
- What is a Death Cross in Stocks?
- 12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming
- What is an Earnings Surprise?
- Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Genmab A/S Right Now?
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
